Myelodysplastic Syndrome
Conditions
Keywords
myelodysplastic syndrome, Transfusion, Hydralazine, valproic acid
Brief summary
Transfusional dependence has been associated closely and independently with low survival in patients with myelodysplastic syndrome (MDS), especially in patients at low risk according to IPSS. Treatment of patients with hydralazine + valproic acid as an alternative to treatment with 5-azacytidine has lower cost and possibly as effective with fewer side effects. The objective of this phase II study is to determine the effectiveness of combination therapy with hydralazine + Ac. Valproic compared with best supportive care. The investigators will select 42 patients per group, and after 14 weeks of treatment the investigators will study in both groups the hematological response (transfusion-dependent, hemoglobin, cytogenetics and morphology) and treatment safety (adverse reactions and vital signs) to 1 year after starting treatment. The concentration of hemoglobin, the number of transfusions, platelets, neutrophils and other continuous variables in both groups will be compared by Student t or Mann-Whitney, as appropriate. For comparison of cytogenetic and morphological response and other categorical variables between groups Chi square will be used. And within each group the investigators will compare each of these variables before and after treatment by t-test for paired data or Wilcoxon test.
Interventions
DRUGBSC
The support group will be receive transfusional BSC, erythropoietin and / or G-CSF as determined by the physician.
DRUGHIDRA/VPA
In each cycle (30 days), Hydralazine 50mg tablets every 12 hours and Valproic 500mg tablets every 8 hours will be administrated orally to HYDRA / VPA group.Each patient will receive 6 cycle.
Sponsors
Basque Health Service
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
1. Ability to understand and voluntarily sign the consent form. 2. Age ≥ 18 years at the time of signing the informed consent form. 3. Ability and willingness to meet the schedule of study visits and other protocol requirements. 4. Documented diagnosis of SMDs according to the criteria of disease risk IPSS intermediate-2, high risk or any risk with transfusion requirements. 5. Transfusion-dependent anemia erythrocytes defined as the absence of a period of 56 consecutive days without transfusion of red blood cells for at least 112 days prior (16 weeks). 6. Engage both women and men to use highly effective contraception. 7. Patients are not candidates for treatment with azacitidine or chemotherapy
Exclusion criteria
* Patients who have any of these
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| change in hemoglobin from baseline in patients who express an erythroid response. | 8 weeks | Independence RBC transfusion requirement for ≥ 8 weeks (56 days) followed by treatment at any time. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Erythroid response according to the criteria of the international working group of SMDs at 24 weeks | 24 weeks | Number and type of administered blood transfusions, time between the last transfusion prior to inclusion in the study and the first transfusion after the 8 weeks of treatment. |
Countries
Spain
Contacts
Primary ContactBreno Moreno de Gusmao, MD
Outcome results
None listed